Zofia Kozak, MD

Psychiatrist

Specialties

Adult Psychiatry
Psychotherapy
Psychodynamic Psychotherapy

Zofia Kozak, MD is a psychiatrist at The Retreat by Sheppard Pratt, where she provides patient-centered care in a therapeutic, residential setting. She completed medical school and psychiatry residency at the University of Maryland/Sheppard Pratt. Dr. Kozak completed a post-baccalaureate research fellowship at the National Institutes of Health (NIH) and is the lead author on several peer-reviewed publications. Her research focuses on emerging, innovative treatments for mood and substance use disorders, with a particular emphasis on psilocybin and MDMA-assisted therapies. Dr. Kozak has worked in a range of clinical settings, including the psychiatric ER and specialized inpatient units, allowing her to treat a wide range of psychiatric conditions with a focus on collaborative treatment approaches. She completed a psychotherapy fellowship through the Washington Baltimore Center for Psychoanalysis and sees outpatients for evaluations, consultations, and clinical management.

Kozak, Z., & Miller, C. W. (2024). Beyond psychedelics: set and setting in general psychiatric practice. International Review of Psychiatry, 1-8. DOI: https://doi.org/10.1080/09540261.2024.2419662

Aaronson, S. T., & Kozak, Z. (2024). New evidence for flexible psilocybin dosing in patients with treatment-resistant depression. Med. PMID: 38359837 DOI: 10.1016/j.medj.2024.01.014

Kozak, Z., & Aaronson, S. T. (2024). The Long Road Toward Equitable MDMA Treatment in the United States. The Journal of Clinical Psychiatry, 85(2), 55022. PMID: 38814108; DOI: 10.4088/JCP.23com15224

Thrul, J., Kozak, Z., Carducci, M. A., Garcia‐Romeu, A., & Yaden, D. B. (2024). Innovations in group‐based psilocybin‐assisted therapy of major depression in patients with cancer. Cancer, 130(7), 1028-1030. PMID: 38105654; DOI: 10.1002/cncr.35127

Kozak, Z., Johnson, M. W., & Aaronson, S. T. (2023). Assessing potential of psilocybin for depressive disorders. Expert Opinion on Investigational Drugs, Jul-Dec;32(10):887-900. PMID: 37869790; DOI: 10.1080/13543784.2023.2273493

Kozak, Z., Urquhart, G. J., Rouhani, S., Allen, S. T., Park, J. N., & Sherman, S. G. (2023). Factors associated with daily use of benzodiazepines/tranquilizers and opioids among people who use drugs. The American Journal on Addictions. PMID: 37717256; DOI: 10.1111/ajad.13483

Kozak, Z., Ciccarone, D., Thrul, J., Cole, T. O., Pappas, A. L., Greenblatt, A. D., ... & Belcher, A. M. (2023). Harm reduction behaviors are associated with carrying naloxone among patients on methadone treatment. Harm reduction journal, 20(1), 1-6. PMID: 36788601; DOI: 10.1186/s12954-023-00745-6

Fioravante, N., Kozak, Z., & Glovinsky, D. (2022). Patients With Schizophrenia-Spectrum Disorders as Vulnerable Populations in an Age of Misinformation: A Case Report of Ivermectin-Related Liver Failure. Journal of the Academy of Consultation-Liaison Psychiatry, 63(6), 639-640. PMID: 36522037; DOI: 10.1016/j.jaclp.2022.08.004

Belcher, A., Cole, T., Greenblatt, A., Hoag, S., Epstein, D., Wagner, M., Billing, A., Massey, E., Hamilton, K., Kozak, Z., … & Colloca, L. (2019). Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment. BMJ open, 9(6), e026604. PMID: 31230007; DOI: 10.1136/bmjopen-2018-026604

Zofia Kozak, MD

Specialties

Address & Contact

Towson Campus

Follow Us